Land: Sverige
Språk: svenska
Källa: Läkemedelsverket (Medical Products Agency)
järn(III)hydroxidpolymaltoskomplex
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
B03AB05
iron (III) hydroxidpolymaltoskomplex
100 mg
Tuggtablett
dextrat, hydratiserat Hjälpämne; järn(III)hydroxidpolymaltoskomplex 357 mg Aktiv substans
Receptbelagt
Förpacknings: Blister, 30 tabletter; Blister, 50 tabletter; Blister, 100 tabletter
Godkänd
2017-11-06
PACKAGE LEAFLET: INFORMATION FOR THE USER FEROFIX 100 MG CHEWABLE TABLETS Iron (III) hydroxide polymaltose complex READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ferofix is and what it is used for 2. What you need to know before you take Ferofix 3. How to take Ferofix 4. Possible side effects 5. How to store Ferofix 6. Content of the pack and other information 1. WHAT FEROFIX IS AND WHAT IT IS USED FOR Ferofix contains the active substance iron, in the form of iron (III) hydroxide polymaltose complex. Iron is an essential element required for the oxygen-carrying capacity of haemoglobine (the red pigment in the blood cells) and of myoglobin (the red pigment in muscle tissue). In iron deficiency the contents of the pigment are decreased and, if the iron deficiency persists, iron deficiency anemia (low level of hemoglobin and depletion of red blood cells) will occur. Ferofix is used in the treatment of iron deficiency in adults and adolescents above the age of 12. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FEROFIX DO NOT TAKE FEROFIX if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6), if iron is overloaded in your body (e.g. hemochromatosis or hemosiderosis), if you have problems in uptake of iron in your body, (e.g. thalassemia), if you have anemia not caused by iron deficiency (e.g. haemolytic anemia – due to hemolysis, with abnormal breakdown of red blood cells – or megaloblastic anemia – a blood disorder with v Läs hela dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ferofix 100 mg chewable tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains Iron (III) hydroxide polymaltose complex equivalent to 100 mg Iron (III). Excipient(s) with known effect Each tablet contains glucose (from dextrates). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablet. Beige/brown spotted, round tablets of approximately 12 mm diameter. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Treatment of iron deficiency in adults and adolescents above the age of 12. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology The dosage and duration of treatment depend on the degree of iron deficiency. Adolescents (> 12 years old) and adults: _Iron deficiency:_ 100 to 300 mg (1 to 3 tablets) daily depending on the severity of the iron deficiency. The effect of treatment should be monitored by laboratory tests, such as haemoglobin and / or iron storage levels, for dose optimisation and duration of treatment. _Paediatric population_ Ferofix 100 mg chewable tablets are not recommended in children aged 12 years old and younger. Method of administration It is recommended to take this medicine during or immediately after a meal, for better absorption. Ferofix 100 mg chewable tablets can be chewed or swallowed whole. 4.3. CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, Patients with iron overload syndromes, e.g. hemochromatosis or hemosiderosis, Patients with iron storage or assimilation diseases, e.g. thalassemia, Patients with anemia not caused by iron deficiency, e.g. haemolytic anemia, or megaloblastic anemia due to vitamin B12 deficiency. 4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE Only patients with iron deficiency with or without anemia should be treated. The reason for iron deficiency should be investigated. In cases of anemia related to inflammation, for example in infections, iron treatment is prefera Läs hela dokumentet